Related Experiment Video
Updated: Jan 30, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Is endocan a biochemical marker for asymptomatic target organ damage in hypertensive patients?
Mustafa Tarık Ağaç1, Behlül Kahyaoğlu, Muhammed Murat Necati Aksoy
1Department of Cardiology, Faculty of Medicine, Sakarya University; Sakarya-Turkey. tarikagac@gmail.com.
Insights
Endocan levels did not differ in asymptomatic hypertensive patients with or without target organ damage. This suggests endocan may not be a useful biomarker in early hypertension stages.
Area of Science:
- Cardiology
- Nephrology
- Vascular Biology
Background:
- Asymptomatic target organ damage (AOD) is crucial for cardiovascular (CV) risk stratification in hypertension.
- Endothelial dysfunction is a key factor in hypertension, and endocan is a novel marker.
- Endocan levels are elevated in hypertensive patients with symptomatic CV and renal disease.
Purpose of the Study:
- To investigate serum endocan levels in asymptomatic hypertensive patients with and without AOD.
- To determine if endocan can serve as a biomarker for early-stage organ damage in hypertension.
Main Methods:
- 132 asymptomatic hypertensive patients were studied.
- 101 patients had at least one form of AOD.
- Serum endocan levels were measured and compared between groups.
Main Results:
- No significant difference in serum endocan levels was observed between hypertensive patients with and without AOD.
- No correlation was found between endocan levels and various AOD-related continuous variables.
- Specific AOD analysis also revealed no significant differences in endocan levels.
Conclusions:
- Endocan may not be a reliable biomarker for detecting asymptomatic vascular damage in hypertension.
- Its utility might be limited to indicating disease severity in advanced symptomatic stages.
- Further research is needed to clarify endocan's role in early hypertensive vascular disease.
Objective:
Identification of the asymptomatic target organ damage (AOD) helps to stratify the overall risk of cardiovascular (CV) diseases and guides a treatment decision in hypertensive patients without a symptomatic CV or renal disease. The endothelial-cell-specific molecule 1 (endocan) is regarded as a novel marker of endothelial dysfunction. Its release is increased in hypertensive patients, especially those with symptomatic CV and renal disease. In the present study, we aimed to evaluate the endocan levels in asymptomatic hypertensive patients with or without AOD.
Methods:
The study included 132 asymptomatic hypertensive patients, and 101 of who had at least one AOD.
Results:
Serum endocan levels did not differ between patients with and without AOD (3.81±0.78 vs. 3.83±0.63 ng/mL, p=0.88). An analysis according to the presence of any specific AOD did not show any difference between groups. No significant correlation was found between serum endocan levels and any of the continuous variables related to AOD, such as the pulse pressure, carotid intimae-media thickness, cardio-ankle vascular index, ankle-brachial index, left ventricular mass index, Sokolow-Lyon index, Cornell voltage-duration product, and estimated glomerular filtration rate.
Conclusion:
Endocan may not serve as a useful biomarker at asymptomatic vascular stages of hypertension, despite its role in indicating disease severity and inflammatory activation in advanced symptomatic CV and renal disease.
Related Concept Videos
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension V: Nursing Management
Levels of Organization
Molecules Are Composed of Atoms, and Biomolecules Are Assembled from Molecules:
The most basic levels include atoms, molecules, and biomolecules. Atoms, the smallest unit of ordinary matter, are composed of a nucleus and electrons. Molecules...
Accessory Organs
Organic Compounds

